Eric Francois was appointed Director of Cero Therapeutics Holdings, Inc., effective February 13, 2026. As of November 14, 2026, Cero Therapeutics Holdings, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 13, 2026, naming 1 appointment (Form 8-K, February 13, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Cero Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cero Therapeutics Holdings, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Cero Therapeutics Holdings, Inc. files it.
Also on the record for Cero Therapeutics Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Tibbs Isaiah | 4.63% of the class | 5%+ stakes | Source |
| March 12, 2026 | Stake report, Schedule 13G, by Tibbs Isaiah | 8.67% of the class | 5%+ stakes | Source |
| December 5, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| July 21, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 6, 2025 | Form D, private offering | $5M sold | Form D page | Source |
| February 5, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| January 21, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 23, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
| November 27, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
| November 25, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 22, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs Cero Therapeutics Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cero Therapeutics Holdings, Inc. and the records around it.
Cero Therapeutics Holdings, Inc. elsewhere on the record
- IPO filing Dec 2025
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Cero Therapeutics Holdings, Inc.
Get an email when Cero Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cero Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cero Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cero Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-13 | In | Director | 2026-02-13 | 8-K, 2026-02-13 |
Who leads Cero Therapeutics Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Eric Francois, appointed, effective 2026-02-13 (filed 2026-02-13).
New leaders reset buying decisions — get the Full Report on Cero Therapeutics Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Cero Therapeutics Holdings, Inc., with the record behind each one.
Find candidates like Director at Cero Therapeutics Holdings, Inc.Every change, in the filing's words
Appointed: Eric Francois, Director, effective 2026-02-13
The board of directors of the Company (the "Board"), approved an increase in the size of the Board from six (6) to seven (7) members and, upon the recommendation of the nominating and corporate governance committee of the Board (the "NCG Committee"), appointed Eric Francois to the newly created seat, in each case, following the acceptance by Mr. Francois of such appointment, effective February 13, 2026.
- Mr. Francois will serve as a director of the Company until the 2026 Annual Meeting of Stockholders, at which time he is expected to stand for election by the Company's stockholders (the "2026 Annual Meeting").
- Subject to confirmation of independence by the NCG Committee and the Board, Mr. Francois will also serve as a member of the Audit Committee.
- Eric Francois was the Managing Director of Raymond James Financial, Inc. between August 2023 and September 2025.
- Prior to that, he was the Managing Director at Credit Suisse between November 2021 and August 2023.
- He previously served as Chief Financial Officer at Scynexis, Inc. between November 2015 to November 2021 and was the co-founder and Chief Operating Officer of Topi, Inc., between July 2013 and October 2015.
- Mr. Francois was an member of board of directors at Diffusion Pharmaceuticals, Inc., between June 2021 and December 2022.
- Mr. Francois served from September 2007 to July 2013 as a Director in the Equity Capital Markets Group at Lazard Ltd where he led capital raisings and advisory assignments for healthcare and biotechnology companies.
- He started his career in September 2000 at Cowen and Company in the Equity Capital Markets and Convertible Debt Groups.
- Mr. Francois holds a B.A. in Economics and Business Administration and a M.A. in Marketing from Pantheon-Sorbonne University, France.
Tools for this story
Each opens in a new tab, filled in for Cero Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
